DexCom (NASDAQ: DXCM) trust plans 2,000-share sale after prior 4,000-share trade

Rhea-AI Filing Summary

DexCom, Inc. (DXCM) has a planned sale of 2,000 shares of common stock through UBS Financial Services, Inc., with an aggregate market value of $160,000.00, listed on NASDAQ and expected on July 31, 2026. The shares originate from vested RSUs granted in 2019 and 2026. A related holder, The Foletta Family Trust dtd 1/30/2015, previously sold 4,000 common shares on June 15, 2026 for $296,539.60.

Key Figures

Shares to be sold: 2,000 shares Aggregate market value: $160,000.00 Vested RSUs (2026 grant): 1,731 shares +3 more

6 metrics

Shares to be sold 2,000 shares Planned sale of DexCom common stock through UBS Financial Services

Aggregate market value $160,000.00 Estimated value of 2,000 DexCom shares to be sold

Vested RSUs (2026 grant) 1,731 shares Vested RSUs dated 05/08/2026 serving as source of sale shares

Vested RSUs (2019 grant) 269 shares Vested RSUs dated 05/31/2019 serving as source of sale shares

Recent shares sold 4,000 shares DexCom common stock sold by The Foletta Family Trust on 06/15/2026

Proceeds from recent sale $296,539.60 Total received for 4,000 DexCom shares sold on 06/15/2026

Key Terms

Vested RSUs, Securities To Be Sold, Securities Sold During The Past 3 Months, Family Trust

4 terms

Vested RSUs financial

"Common | 05/08/2026 | Vested RSUs | Issuer"

Securities To Be Sold regulatory

"144: Securities To Be Sold"

Securities Sold During The Past 3 Months regulatory

"144: Securities Sold During The Past 3 Months"

Family Trust financial

"The Foletta Family Trust dtd 1/30/2015"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/31/2026 - 04:07 PM Accepted by SEC EDGAR 07/31/2026 - 04:06 PM Learn about SEC filing dates

FAQ

What stock sale is disclosed for DexCom (DXCM) in this Form 144 filing?

The filing reports a planned sale of 2,000 shares of DexCom common stock with an aggregate market value of $160,000.00, to be executed through UBS Financial Services on or about July 31, 2026.

What is the source of the 2,000 DexCom (DXCM) shares to be sold?

The 2,000 DexCom shares come from vested RSUs: 1,731 RSUs vesting on May 8, 2026 and 269 RSUs vesting on May 31, 2019, all issued by DexCom.

Which brokerage is handling the planned DexCom (DXCM) stock sale?

The planned sale of 2,000 DexCom shares is to be handled by UBS Financial Services, Inc., located at 11 Madison Ave, 4th Floor, New York, NY 10010, with the stock listed on NASDAQ.

What prior DexCom (DXCM) stock sale is reported for the past three months?

The filing notes that The Foletta Family Trust dtd 1/30/2015 sold 4,000 DexCom common shares on June 15, 2026, receiving proceeds of $296,539.60 in that transaction.

Who is the selling security holder mentioned in the DexCom (DXCM) Form 144 data?

The section on prior sales references The Foletta Family Trust dtd 1/30/2015, located at 6340 Sequence Drive, San Diego, CA 92121, as having sold DexCom common shares on June 15, 2026.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	2000	160000.00	377360765	07/31/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/08/2026	Vested RSUs	Issuer			1731	05/08/2026	N/A
Common	05/31/2019	Vested RSUs	Issuer			269	05/31/2019	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
The Foletta Family Trust dtd 1/30/2015 6340 SEQUENCE DRIVE SAN DIEGO CA 92121	Common	06/15/2026	4000	296539.60

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)